先聲藥業(02096.HK)附屬就轉讓北京托畢西藥業爭議仲裁勝訴
先聲藥業(02096.HK)公布,有關其附屬先聲藥業2017年7月與子博、東菱藥品及千賀博文(被申請人)簽署的轉讓目標公司北京托畢西藥業100%股權的《股權轉讓協議》及《合作協議》爭議,先聲藥業於2月22日接獲上海國際仲裁中心的一項仲裁裁決,裁定子博繼續履行,將其對目標公司的100%股權轉讓予先聲藥業;東菱藥品及千賀博文對所涉《股權轉讓協議》的繼續履行義務承擔連帶責任。
該裁決為終局裁決,自作出之日起生效。
早於2020年3月27日,因被申請人違約,上仲委員會曾就該等協議做出裁定(前案),要求被申請人按照該等協議連帶支付5,000萬元人民幣的特別違約金。前案仲裁裁決被申請人尚未履行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.